From: The potential of cystatin C as a predictive biomarker in pulmonary hypertension
Variables | Total (N = 398) | CW (n = 72) | No-CW (n = 326) | P-value |
---|---|---|---|---|
CKD stages, n (%)a | Â | Â | Â | 0.010 |
 Stage 1 | 159 (39.9) | 17 (23.6) | 142 (43.6) |  |
 Stage 2 | 186 (46.7) | 41 (56.9) | 145 (44.5) |  |
 Stage 3 | 51 (12.8) | 14 (19.4) | 37 (11.3) |  |
 Stage 4 | 2 (0.5) | 0 (0.0) | 2 (0.6) |  |
eGFR, mL/min/1.73m2 | ||||
 2009 CKD-EPIcr | 80.64 ± 21.93 | 76.00 ± 22.14 | 81.67 ± 21.79 | 0.047 |
 2012 CKD-EPIcys | 81.94 ± 26.34 | 73.35 ± 26.74 | 83.75 ± 25.89 | 0.002 |
 2012 CKD-EPIcr-cys | 81.10 ± 22.82 | 74.21 ± 23.24 | 82.62 ± 22.47 | 0.005 |
 2021 CKD-EPIcr | 84.61 ± 22.06 | 80.19 ± 22.45 | 85.59 ± 21.89 | 0.060 |
 2021 CKD-EPIcr-cys | 84.15 ± 23.10 | 77.12 ± 23.69 | 85.71 ± 22.71 | 0.004 |
 MDRD | 78.57 ± 22.16 | 74.72 ± 22.06 | 79.42 ± 22.13 | 0.103 |
 Cockcroft-Gault | 78.96 ± 36.34 | 75.31 ± 38.18 | 79.77 ± 35.95 | 0.347 |